The role of LINC01419 in regulating the cell stemness in lung adenocarcinoma through recruiting EZH2 and regulating FBP1 expression

Springer Science and Business Media LLC - Tập 17 - Trang 1-12 - 2022
Zhao Chen1, Weijian Tang1, Yuhan Zhou1, Zhengfu He1
1Department of Thoracic Surgery, Sir Run Run Shaw Hospital School of Medicine, Zhejiang University, Hangzhou, China

Tóm tắt

Recent years have witnessed a growing academic interest in the effects of lncRNAs on tumors. LINC01419 is found to facilitate proliferation and metastasis of lung adenocarcinoma (LUAD) cells, but there is a great deal of uncertainty about how LINC01419 works on LUAD cell stemness. For this reason, the focus of this research is centered on the regulatory impact of LINC01419 on LUAD cell stemness. For the detection of the expression level of LINC01419 in LUAD, qRT-PCR was performed. And how oe-LINC01419 and sh-LINC01419 affected LUAD cell proliferation as well as stem cell sphere-formation were examined by CCK-8 and cell sphere-forming assays. In addition, whether LINC01419 could recruit EZH2 and regulate FBP1 expression were determined by bioinformatics analysis, RNA immunoprecipitation (RIP), and chromatin immunoprecipitation (ChIP). Western blot was utilized to detect the protein expression levels of FBP1, CD44, CD133, and ALDH-1 as well. On the basis of the findings from those assays, an up-regulation of LINC01419 level was demonstrated in LUAD cell lines, and a remarkable upregulation of it in CD44 + LUAD cells. In LUAD cells, proliferation and stem cell sphere-formation that were attenuated by LINC01419 knockdown were discovered to be facilitated by LINC01419 overexpression. And a binding relationship between LINC01419 and EZH2 was determined by RIP assay. Besides, EZH2 was capable of binding to FBP1 promoter region, as found by ChIP-PCR assay. Finally, it was demonstrated by in vitro experiments that LINC01419 could inhibit FBP1 expression by recruiting EZH2, resulting in promotion of LUAD cell proliferation and stemness. To summarize, our findings demonstrate a cancer-promoting role of LINC01419 in LUAD. LINC01419, by recruiting EZH2 and regulating FBP1 expression, contributes to LUAD cell stemness. According to these findings, the potential of LINC01419 to be the target for LUAD treatment is hence determined, which also adds more possibility to the enrichment of therapeutic strategies for lung cancer stem cells.

Tài liệu tham khảo

Zakaria N, et al. Targeting lung cancer stem cells: research and clinical impacts. Front Oncol. 2017;7:80. https://doi.org/10.3389/fonc.2017.00080. Li N, Zhu Y. Targeting liver cancer stem cells for the treatment of hepatocellular carcinoma. Therap Adv Gastroenterol. 2019;12:1756284818821560. https://doi.org/10.1177/1756284818821560. Sanches JGP, et al. The role of KDM2B and EZH2 in regulating the stemness in colorectal cancer through the PI3K/AKT pathway. Front Oncol. 2021;11:637298. https://doi.org/10.3389/fonc.2021.637298. Wang R, Dong HX, Zeng J, Pan J, Jin XY. LncRNA DGCR5 contributes to CSC-like properties via modulating miR-330-5p/CD44 in NSCLC. J Cell Physiol. 2018;233:7447–56. https://doi.org/10.1002/jcp.26590. Zhou H, et al. LncRNA-cCSC1 modulates cancer stem cell properties in colorectal cancer via activation of the Hedgehog signaling pathway. J Cell Biochem. 2020;121:2510–24. https://doi.org/10.1002/jcb.29473. Zhao L, Lou G, Li A, Liu Y. lncRNA MALAT1 modulates cancer stem cell properties of liver cancer cells by regulating YAP1 expression via miR375 sponging. Mol Med Rep. 2020;22:1449–57. https://doi.org/10.3892/mmr.2020.11196. Cheng Z, et al. LINC01419 promotes cell proliferation and metastasis in lung adenocarcinoma via sponging miR-519b-3p to up-regulate RCCD1. Biochem Biophys Res Commun. 2019;520:107–14. https://doi.org/10.1016/j.bbrc.2019.09.090. Li Z, et al. Post-translational modifications of EZH2 in cancer. Cell Biosci. 2020;10:143. https://doi.org/10.1186/s13578-020-00505-0. Eich ML, Athar M, Ferguson JE 3rd, Varambally S. EZH2-targeted therapies in cancer: hype or a reality. Cancer Res. 2020;80:5449–58. https://doi.org/10.1158/0008-5472.CAN-20-2147. Thornton SR, Butty VL, Levine SS, Boyer LA. Polycomb Repressive Complex 2 regulates lineage fidelity during embryonic stem cell differentiation. PLoS ONE. 2014;9: e110498. https://doi.org/10.1371/journal.pone.0110498. Lee TI, et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell. 2006;125:301–13. https://doi.org/10.1016/j.cell.2006.02.043. Boyer LA, et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature. 2006;441:349–53. https://doi.org/10.1038/nature04733. Ezhkova E, et al. Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell. 2009;136:1122–35. https://doi.org/10.1016/j.cell.2008.12.043. Kaneko S, et al. Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA. Genes Dev. 2010;24:2615–20. https://doi.org/10.1101/gad.1983810. Lv L, et al. Long non-coding RNA LINC00114 facilitates colorectal cancer development through EZH2/DNMT1-induced miR-133b suppression. Front Oncol. 2019;9:1383. https://doi.org/10.3389/fonc.2019.01383. Yang C, et al. USP44 suppresses pancreatic cancer progression and overcomes gemcitabine resistance by deubiquitinating FBP1. Am J Cancer Res. 2019;9:1722–33. Li Q, et al. The FOXC1/FBP1 signaling axis promotes colorectal cancer proliferation by enhancing the Warburg effect. Oncogene. 2019;38:483–96. https://doi.org/10.1038/s41388-018-0469-8. Fu D, et al. HMGB2 is associated with malignancy and regulates Warburg effect by targeting LDHB and FBP1 in breast cancer. Cell Commun Signal. 2018;16:8. https://doi.org/10.1186/s12964-018-0219-0. Yasuda T, Ishimoto T, Baba H. Conflicting metabolic alterations in cancer stem cells and regulation by the stromal niche. Regen Ther. 2021;17:8–12. https://doi.org/10.1016/j.reth.2021.01.005. Peng F, et al. Glycolysis gatekeeper PDK1 reprograms breast cancer stem cells under hypoxia. Oncogene. 2018;37:1119. https://doi.org/10.1038/onc.2017.407. Wang M, et al. Long non-coding RNA H19 confers 5-Fu resistance in colorectal cancer by promoting SIRT1-mediated autophagy. Cell Death Dis. 2018;9:1149. https://doi.org/10.1038/s41419-018-1187-4. Zhu Y, et al. LINC00968 can inhibit the progression of lung adenocarcinoma through the miR-21-5p/SMAD7 signal axis. Aging (Albany NY). 2020;12:21904–22. https://doi.org/10.18632/aging.104011. Wu J, Sun L, Liu T, Dong G. Ultrasound-targeted microbubble destruction-mediated downregulation of EZH2 inhibits stemness and epithelial-mesenchymal transition of liver cancer stem cells. Onco Targets Ther. 2021;14:221–37. https://doi.org/10.2147/OTT.S269589. Deng X, et al. A KLF4/PiHL/EZH2/HMGA2 regulatory axis and its function in promoting oxaliplatin-resistance of colorectal cancer. Cell Death Dis. 2021;12:485. https://doi.org/10.1038/s41419-021-03753-1. Li W, et al. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. Sci Rep. 2017;7:13856. https://doi.org/10.1038/s41598-017-14364-2. Xiong X, et al. GSK343 induces programmed cell death through the inhibition of EZH2 and FBP1 in osteosarcoma cells. Cancer Biol Ther. 2020;21:213–22. https://doi.org/10.1080/15384047.2019.1680061. Wang N, et al. Long noncoding RNA DANCR regulates proliferation and migration by epigenetically silencing FBP1 in tumorigenesis of cholangiocarcinoma. Cell Death Dis. 2019;10:585. https://doi.org/10.1038/s41419-019-1810-z. Dzobo K, Ganz C, Thomford NE, Senthebane DA. Cancer stem cell markers in relation to patient survival outcomes: lessons for integrative diagnostics and next-generation anticancer drug development. OMICS. 2021;25:81–92. https://doi.org/10.1089/omi.2020.0185. Wang X, et al. miR-181b/Notch2 overcome chemoresistance by regulating cancer stem cell-like properties in NSCLC. Stem Cell Res Ther. 2018;9:327. https://doi.org/10.1186/s13287-018-1072-1. Qiu Y, Yang L, Liu H, Luo X. Cancer stem cell-targeted therapeutic approaches for overcoming trastuzumab resistance in HER2-positive breast cancer. Stem Cells. 2021;39:1125–36. https://doi.org/10.1002/stem.3381. Chen J, Chen H, Yang H, Dai H. SPC25 upregulation increases cancer stem cell properties in non-small cell lung adenocarcinoma cells and independently predicts poor survival. Biomed Pharmacother. 2018;100:233–9. https://doi.org/10.1016/j.biopha.2018.02.015. Zhao S, Shen W, Yu J, Wang L. TBX21 predicts prognosis of patients and drives cancer stem cell maintenance via the TBX21-IL-4 pathway in lung adenocarcinoma. Stem Cell Res Ther. 2018;9:89. https://doi.org/10.1186/s13287-018-0820-6. Herreros-Pomares A, et al. Lung tumorspheres reveal cancer stem cell-like properties and a score with prognostic impact in resected non-small-cell lung cancer. Cell Death Dis. 2019;10:660. https://doi.org/10.1038/s41419-019-1898-1. Yoo KH, Hennighausen L. EZH2 methyltransferase and H3K27 methylation in breast cancer. Int J Biol Sci. 2012;8:59–65. https://doi.org/10.7150/ijbs.8.59. Yang LN, Ning ZY, Wang L, Yan X, Meng ZQ. HSF2 regulates aerobic glycolysis by suppression of FBP1 in hepatocellular carcinoma. Am J Cancer Res. 2019;9:1607–21. Dong C, et al. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell. 2013;23:316–31. https://doi.org/10.1016/j.ccr.2013.01.022.